News

A BMJ survey of 1,000 GPs found that twenty per cent of GPs have used GenAI in clinical practice, but according to polls we should be OK with it!The survey, published last week, said that of those GPs who used GenAI, nearly an equal number used it for differential diagnosis and generating ...

Read more

A reminder that a not-to-be-missed webinar takes place next week!Candesic Senior Partner Dr Michelle Tempest will be kicking off the Royal Society of Medicine 'Insights into AI healthcare: Patient perspectives and clinical realities' event on Tuesday next week.Delve ...

Read more

Candesic Managing Partner Dr Leonid Shapiro and Principal Dr Joe Taylor explore the intriguing applications of cerebral organoids in the latest edition of PharmaTimes.These artificially grown minibrains have the potential to guide drug discovery, and lead to a powerful new generation of ...

Read more

What does the EU framework for AI innovation and regulation mean for the future of healthcare in Europe? Dr Leonid Shapiro, Managing Partner at Candesic, provides his views on the potential impact of the proposed regulation in Healthcare Business International. “This is a very fast-moving ...

Read more

Candesic Managing Partner Dr Leonid Shapiro and Principal Dr Joe Taylor discuss in an article in PharmaTimes Media Ltd how quantum computers can contribute to the development of new medicines – and potentially replace existing AI drug discovery platforms.

Read more

Candesic Senior Partner Dr Michelle Tempest joined Abdul Rahyead as a guest on a new episode of The Scrubbed In Show Podcast. The conversation centered on the transition from a career in acute psychiatry to becoming a management consultant, on her passion for making a positive impact ...

Read more

Candesic Senior Partner and Cambridge Angels Investor Dr Michelle Tempest, featured in a report reviewing the UK's AI corporate ecosystem. The report was brought by Barclays Eagle Labs, UK Government and Beauhurst. The global landscape of artificial intelligence is rapidly evolving, and ...

Read more

HealthInvestor features Dr Michelle Tempest, Senior Partner at Candesic, commenting on the government’s AI Life Sciences Accelerator Mission £100 million fund. The fund will provide a strong boost to UK life sciences and healthcare AI investment, and contribute to further healthcare ...

Read more

Government initiatives such as the £100m investment programme to accelerate use of AI in life sciences, and the AI Safety Summit to be held today and tomorrow, underscore the critical importance of driving and embracing AI's vast opportunities. Candesic's continued work in healthcare AI is ...

Read more

andesic team, Dr Michelle Tempest and Juliet Frances Thornton in the new LaingBuisson HealthcareMarkets UK investigate the opportunities of electronic health records and a new era of

Read more